To Stent or Not To Stent
Regina S Druz, MD, FACC, FASNC
PDF
HTML

Keywords

Heart disease
ISCHEMIA trial
Integrative cardiology
Stents
PDF
HTML

Abstract

Ischemic heart disease is the number one cause of mortality in both genders. Despite substantial gains in reducing mortality from cardiovascular disease, its prevalence is on the rise. Although percutaneous coronary revascularization procedures revolutionized the approach to acute coronary artery disease (CAD), their role in stable, chronic disease is less defined. As many more patients live on with stable forms of CAD, it is imperative that practitioners understand current evidence for and against revascularization, and develop a holistic, integrative approach to CAD. We examine current knowledge guiding decision-making in chronic CAD, and expand upon potential use of integrative approaches to chronic CAD.

PDF
HTML

References

Gruppo Italiano per lo Studio della Streptochinasi nell’Infarto Miocardico (GISSI). Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Lancet. 1986; 8478:397–402.
An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. The GUSTO investigators. N Engl J Med. 1993; 329:673–82.
Fassa AA, Wijns W, Kolh P, et al. Benefit of revascularization for stable ischaemic heart disease: the jury is still out. Eur Heart J. 2013; 34:153–48.
ISCHEMIA trial (executive summary). April 2014. Available from www.ischemiatrial.org .
Gibbons RJ, Miller TD. Should extensive myocardial ischaemia prompt revascularization to improve outcomes in chronic coronary artery disease? Eur Heart J. 2015; 36:228–17.
Hochman JS. The Ischemia Trial – CCC. Available from www.ischemiatrial.org .
Stergiopoulos K, Boden WE, Hartigan P, et al. Percutaneous coronary intervention outcomes in patients with stable obstructive coronary artery disease and myocardial ischemia. A collaborative meta-analysis of contemporary randomized clinical trials. JAMA Intern Med. 2014; 174:232–40.
Boden WE, O’Rourke RA, Teo KK, et al., for the COURAGE Trial Research Group. Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med. 2007; 356:1503–16.
BARI 2D Study Group; Frye RL, August P, Brooks MM, et al. A randomized trial of therapies for type 2 diabetes and coronary artery disease. N Engl J Med. 2009; 360:250–15.
Sedlis SP, Hartigan PM, Teo KK, et al. COURAGE Trial Investigators. Effect of PCI on long-term survival in patients with stable ischemic heart disease. N Engl J Med. 2015; 373:1937–46.
Maron DJ, Stone GW, Berman DS, et al. Is cardiac catheterization necessary before initial management of patients with stable ischemic heart disease? Results from a web-based survey of cardiologists. Am Heart J. 2011; 162:1034–43.
Eckel RH, Jakicic JM, Ard JD, et al. American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2013 AHA/ACC Guideline on Lifestyle Management to Reduce Cardiovascular Risk. J Am Coll Cardiol. 2014; 63:2960–84.

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY-NC-ND 4.0). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.